News >

COTA, FDA Agree to Collaborate on Breast Cancer Research

Jason Harris
Published: Thursday, May 30, 2019

Mike Doyle

Mike Doyle

COTA, Inc., a leading precision medicine technology company, has signed a 2-year Research Collaboration Agreement (RCA) with the FDA’s Information Exchange and Data Transformation (INFORMED) program. The agreement establishes a study protocol for research into disparities in treatment and outcomes for patients with breast cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances In™ Tumor Testing: Interpreting Genomic Profiles to Optimize Breast Cancer TreatmentJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication